Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of BigBear.ai Holdings, Inc. regarding a class action lawsuit due to alleged misleading statements and accounting errors during a specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from March 31, 2022, to March 25, 2025 [3]. - Allegations include that BigBear maintained deficient accounting review policies, leading to incorrect accounting for the 2026 Convertible Notes and misstatements in financial statements [3]. Financial Reporting Issues - The company allegedly failed to disclose that the conversion option within the 2026 Convertible Notes did not qualify for the derivative scope exception under ASC 815-40, resulting in improper accounting [3]. - As a consequence, BigBear's financial statements were inaccurate and likely to require restatement, increasing the risk of delays in filing reports with the SEC [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by June 10, 2025, to monitor the case's progress [4]. - Registration allows shareholders to receive updates and does not incur any costs or obligations [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [5].

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Avis Budget Group, Inc. (NASDAQ: CAR). Shareholders who purchased shares of CAR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/avis-budget-loss-submission-form/?id=151934&from=3 CLASS PERIOD: February 16 ...

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI). Shareholders who purchased shares of TMCI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/treace-medical-concepts-inc-loss-submission-form-2/?id=151932&from=3 ...

NEW YORK, June 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Napco Security Technologies, Inc. (NASDAQ: NSSC).Shareholders who purchased shares of NSSC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/napco-security-technologies-inc-loss-submission-form/?id=151911&from=4CL ...

NEW YORK, June 5, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Strategy Incorporated (NASDAQ: MSTR). Shareholders who purchased shares of MSTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/strategy-incorporated-loss-submission-form/?id=151576&from=4 CLASS PERIOD: April ...

URGN Investors with Losses Encouraged to Contact Hagens BermanSAN FRANCISCO, May 29, 2025 /PRNewswire/ -- On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ: URGN) saw the price of their shares crash 44% after the company announced that the FDA's Oncologic Drugs Advisory Committee ("ODAC") voted against the risk/benefit profile of UroGen's UGN-102, a therapy intended to treat patients with low-grade, intermediate-risk non-muscle invasive bladder cancer ("LG-IR-NMIBC") for which no drugs are currently ...

Core Points - The Gross Law Firm has issued a notice to shareholders of Ibotta, Inc. regarding a class action lawsuit related to the company's initial public offering on April 18, 2024 [1][3] - The lawsuit alleges that Ibotta made false statements and failed to disclose the risks associated with its contract with Kroger, specifically that the contract was at-will and could be terminated without warning [4] - Shareholders are encouraged to register for the class action by June 16, 2025, to potentially become lead plaintiffs and receive updates on the case [5] Company and Industry Summary - Ibotta, Inc. is facing legal challenges due to allegations of misleading investors about the nature of its contract with Kroger, which could impact investor confidence and stock performance [4] - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to misleading statements from companies like Ibotta [6]

SAN FRANCISCO, May 22, 2025 (GLOBE NEWSWIRE) -- On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ: URGN) saw the price of their shares crash 44% after the company announced that the FDA’s Oncologic Drugs Advisory Committee (“ODAC”) voted against the risk/benefit profile of UroGen’s UGN-102, a therapy intended to treat patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (“LG-IR-NMIBC”) for which no drugs are currently FDA-approved. Hagens Berman has opened an investigation in ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering, which may have artificially deflated the stock price prior to a merger announcement with AbbVie Inc. [1][2] Group 1: Allegations and Impact - Cerevel's October 16, 2023 secondary stock offering documents allegedly omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, leading to an artificial deflation of Cerevel's stock price [2] - Bain Capital, Cerevel's controlling shareholder, reportedly acquired shares at this artificially depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [2] - The January 18, 2024 Proxy statement from Cerevel is claimed to have misled investors regarding the nature and timing of AbbVie's interest in the company [2] Group 2: Class Action Details - The class period for the lawsuit includes shareholders who sold or disposed of Cerevel stock from October 11, 2023, to August 1, 2024, and those who held shares as of January 8, 2024, entitled to vote on the merger [1] - The deadline for shareholders to register for the class action and seek lead plaintiff status is June 3, 2025, with no cost or obligation to participate [3] - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's status [3]

LOS ANGELES, May 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cleveland-Cliffs Inc. ("Cleveland-Cliffs" or "the Company") (NYSE: CLF) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cleveland-Cliffs reportd its financial results for Q1 2025 on May 7, 20 ...